Login / Signup
Quality of life should be the primary outcome for disease-modifying therapy trials in MS-Yes.
Yael Goverover
Nancy D Chiaravalloti
Published in:
Multiple sclerosis (Houndmills, Basingstoke, England) (2023)
Keyphrases
</>
mass spectrometry
multiple sclerosis
ms ms
stem cells
chemotherapy induced